Breaking Finance News

Robert W. Baird disclosed BeiGene (NASDAQ:BGNE), boosting its price target to $83.00 earlier today

Reporting a potential downside of -0.10%, Robert W. Baird upped the price target of BeiGene (NASDAQ:BGNE) to $83.00

Previously on Thursday September 28, 2017, Maxim Group reported on BeiGene (NASDAQ:BGNE) increased the target price from $77.00 to $120.00. At the time, this indicated a possible upside of 0.20%.

Just yesterday BeiGene (NASDAQ:BGNE) traded -3.78% lower at $92.30. BeiGene’s 50-day moving average is $77.30 and its 200-day moving average is $77.30. The last closing price is up 24.51% relative to the two hundred day average, compared with the S&P 500 Index which has increased 0.02% over the same period. Volume of trade was up over the average, with 275,902 shares of BGNE changing hands over the typical 232,286

Performance Chart

BeiGene (NASDAQ:BGNE)

With a total market value of $0, BeiGene has 52 week low of $26.43 and a 52 week high of $102.00 .

About BeiGene (NASDAQ:BGNE)

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016. BGB-3111, BGB-290 and BGB-283 are its molecularly targeted agents and is its immuno-oncology agent. BGB-3111 is a potent and highly selective small molecule inhibitor of Bruton's tyrosine kinase (BTK). BGB-283 is a molecule inhibitor of both the monomer and dimer forms of the RAF kinase. BGB-290 is a molecularly targeted, orally available, potent and highly selective inhibitor of the poly ADP ribose polymerase (PARP) family members. BGB-A317 is an investigational humanized monoclonal antibody against the immune checkpoint receptor, PD-1.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *